Premium
Verubecestat fails to slow progression of disease in prodromal Alzheimer's
Publication year - 2019
Publication title -
the brown university psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7532
pISSN - 1068-5308
DOI - 10.1002/pu.30456
Subject(s) - placebo , medicine , disease , dementia , adverse effect , alzheimer's disease , psychiatry , oncology , alternative medicine , pathology
Verubecestat reduces amyloid‐beta levels in the brain in healthy individuals and in patients with Alzheimer's disease, but a placebo‐controlled trial has found that the drug did not slow progression of dementia in patients who were at a prodromal stage of Alzheimer's disease. The research team terminated the trial for futility after finding more adverse outcomes in the medication group than in the placebo group. Study results were published April 11 in The New England Journal of Medicine .